The Effect of Mesalamine and Nicotine in the Treatment of Inflammatory Bowel Disease

@article{Bonapace1997TheEO,
  title={The Effect of Mesalamine and Nicotine in the Treatment of Inflammatory Bowel Disease},
  author={C. Bonapace and D. Mays},
  journal={Annals of Pharmacotherapy},
  year={1997},
  volume={31},
  pages={907 - 913}
}
OBJECTIVE: To characterize the usefulness of mesalamine and nicotine in the treatment of active ulcerative colitis and inactive Crohn's disease. DATA SOURCES: Citations were selected from the MEDLINE database. Only those involving human subjects, inflammatory bowel disease, and available in English were selected. STUDY SELECTION: Selection criteria consisted of clinical trials and review articles assessing the effects of mesalamine and nicotine in active ulcerative colitis or inactive Crohn's… Expand
An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease
TLDR
Nicotine reduced inflammation in the TNBS model of colonic damage confirming the use of nicotine in IBD although the choice of dose requires further investigation. Expand
Clinical economics review: medical management of inflammatory bowel disease
Inflammatory bowel diseases, although they are uncommon and rarely fatal, typically present during the period of economically productive adult life. Patients may require extensive therapeuticExpand
Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis
TLDR
A greater understanding of the pharmacodynamics and kinetics of nicotine in relation to the immune system and enhanced knowledge of gut permeability defects in UC are required to establish the exact protective nature of nicotine and its metabolites in UC. Expand
Transport Mechanisms of Nicotine across the Human Intestinal Epithelial Cell Line Caco-2
TLDR
To characterize the disposition of nicotine in the intestines, intestinal nicotine transport using Caco-2 cells is investigated and specific uptake systems appear to be distinct from organic cation transporters and the transport system for tertiary amines, in terms of its substrate specificity and the pattern of the interaction. Expand
The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
Specific interventions included in the review Studies were included if they examined bupropion (150 or 300 mg/day) immediate release and SR formulations, used to aid smoking cessation alone, or asExpand
Involvement of Neuronal Nicotinic Receptors in Disease
TLDR
Those diseases in which the association is well established are discussed in detail in this chapter and others, in which nAChR involvement is inferred on the basis of indirect evidence, are mentioned in brief. Expand
A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice.
TLDR
It is suggested that smoking increases the risk of inflammation-related colon cancer development and the effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone on colon carcinogenesis were examined using an AOM/dextran sulfate sodium (DSS) mouse model. Expand
Neuronal nicotinic receptors: from structure to pathology
TLDR
This review will attempt to survey the major achievements reached in the study of the structure and function of NAChRs by examining their regional and cellular localisation and the molecular basis of their functional diversity mainly in pharmacological and biochemical terms. Expand
Nicotine can skew the characterization of the macrophage type-1 (MPhi1) phenotype differentiated with granulocyte-macrophage colony-stimulating factor to the MPhi2 phenotype.
TLDR
It is reported that nicotine, the major ingredient of cigarette smoke, can modulate the characteristics of MPhi1 and proposed that nicotine is a potent regulator that modulates immune responses in microenvironments. Expand
Nicotine Evoked Currents in Human Primary Sensory Neurons.
TLDR
The results suggest that there are not only species differences in the sensory neuron distribution of nA ChR currents between rodent and human, but that the subunit composition of the channel underlying human nAChR currents may be different from those in the mouse or rat. Expand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
TLDR
Both rectal mesalamine and oral olsalazine provide clinicians with an effective therapeutic option for the treatment of ulcerative colitis, proctosigmoiditis, and proctitis in patients unresponsive to or intolerant of the effects of sulfasalazine or corticosteroids. Expand
Transdermal nicotine for active ulcerative colitis.
TLDR
The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis. Expand
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
TLDR
This controlled-release mesalamine preparation is safe and effective at 4 g/day as a single agent in treatment of active Crohn's disease of the ileum and colon. Expand
Long-term use of mesalamine enemas to induce remission in ulcerative colitis.
TLDR
Extending mesalamine treatment to at least 34 weeks was beneficial in inducing a complete remission in 80% of patients unresponsive to conventional therapy. Expand
Transdermal nicotine as maintenance therapy for ulcerative colitis.
TLDR
Transdermal nicotine alone was no better than placebo in the maintenance of remission of ulcerative colitis, and premature withdrawal due to side effects was more common in the nicotine group. Expand
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
TLDR
The data suggest that controlled-release mesalamine capsules are a safe and effective monotherapy in doses of 2-4 g daily for treating mild to moderately active ulcerative colitis, as well as for inducing remission, regardless of prior oral steroid or sulfasalazine therapy or extent of disease. Expand
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)
TLDR
Pentasa (2 g/day for 2 years) is a safe and effective maintenance treatment for Crohn's disease when given within 3 months of achieving remission, showing there was a significant benefit from Pentasa in the high relapse risk stratum. Expand
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
TLDR
After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups. Expand
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
TLDR
Colon-targeted oral mesalamine at 2.4 g/d is effective therapy for mildly to moderately active ulcerative colitis and should provide a viable therapeutic alternative to sulfasalazine. Expand
A meta-analysis of the role of smoking in inflammatory bowel disease
  • B. Calkins
  • Medicine
  • Digestive diseases and sciences
  • 1989
TLDR
There is no justification for health care providers to change the Surgeon General's recommendations on smoking or tobacco use for ulcerative colitis patients specifically and a review of the literature, meta-analysis of selected studies, and assessment of causality criterion suggest that not smoking and ulceratives colitis and smoking and Crohn's disease are consistent with a causal relationship. Expand
...
1
2
3
4
...